Moreover, a prognostic model incorporating BATF, EGR1, PD-1, PD-L1, and TIM-3 calculated a risk score, with high-risk patients demonstrating significantly shorter OS than low-risk patients in both total AML patients and allo-HSCT recipients (P < 0.001). The gene discussed is PDCD1; the disease is acute myeloid leukemia.